TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as SecondLine Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma

TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as SecondLine Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma

Saved in:
Bibliographic Details
Published in:BLOOD Vol. 142
Main Authors: Morschhauser, F, Dahiya, S, Palomba, ML, Garcia-Sancho, AM, Reguera, JL, Kuruvilla, J, Jaeger, U, Cartron, G, Izutsu, K, Dreyling, M, Kahl, BS, Ghesquieres, H, Ardeshna, K, Goto, H, Barbui, AM, Abramson, JS, Borchmann, P, Fleury, I, Mielke, S, Skarbnik, A, de Vos, S, Kamdar, M, Karmali, R, Viardot, A, Farazi, T, Fasan, O, Lymp, J, Vedal, M, Nishii, R, Avilion, A, Papuga, J, Nastoupil, LJ
Format: Conference Proceeding
Language:English
Published: 2023
Subjects:
Medicin och hälsovetenskap
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0006-4971
DOI:10.1182/blood-2023-179474